Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2020-11-05 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
App 2A quotation for shares issued in strategic transaction 15 pages 228.2KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of new securities, referencing previous announcements (Appendix 3B) and the nature of the securities being quoted. This type of document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of Capital/Financing Update (CAP) as it provides updates on the issuance and quotation of securities, which is a capital structure change.
2020-11-05 English
Investor Briefing - Asia Strategy 15 pages 2.5MB
Investor Presentation Classification · 95% confidence The document is titled 'Telix Pharmaceuticals Limited Investor Briefing: Asia Strategy' dated 3rd November 2020. It contains detailed information about a strategic partnership with China Grand Pharma, including commercial agreements, equity investments, product portfolios, market strategy, and operational impacts. The content is presented as a detailed presentation with forward-looking statements, market analysis, and strategic plans. There are no financial statements, audit opinions, or regulatory certifications included. The document is clearly a presentation aimed at investors focusing on financials, strategy, and market position rather than a formal report or announcement. Therefore, the document fits the definition of an Investor Presentation (IP).
2020-11-02 English
Appendix 2A - issue of shares on exercise of options 15 pages 219.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A Application for quotation of securities' and is addressed to the ASX (Australian Securities Exchange). It details the application for quotation of securities resulting from options exercised or convertible securities converted. The content includes specific information about the securities, exercise prices, expiry dates, and dates of conversion. This type of document is a formal announcement to the exchange regarding the issuance and quotation of new securities, not a financial report or earnings release. It fits the category of a Share Issue/Capital Change announcement, as it relates to new shares being issued and quoted on the exchange.
2020-11-02 English
Cleansing Notice - issue of shares from exercise of options 1
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A of the Corporations Act regarding the issuance of shares upon exercise of options. It references an Appendix 2A and compliance with disclosure provisions but does not contain financial statements or detailed financial data. The document is short (1269 characters) and serves as a regulatory announcement about share issuance without disclosure. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2020-11-02 English
Appendix 3Y - change in Director interests - O Buck 2 pages 212.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the exercise of options and resulting shareholdings. The content focuses on personal share transactions by a director, including dates, number of shares/options acquired, and nature of the transaction. There is no financial performance data, earnings information, or report publication. The document matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3617 characters, which is consistent with a detailed insider trading notice rather than a full report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2020-11-02 English
Strategic Licence and Partnership for Greater China Market 3 pages 241.9KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of a strategic commercial partnership and equity investment between Telix Pharmaceuticals Limited and China Grand Pharmaceutical and Healthcare Holdings Limited. It outlines terms of the partnership, milestone payments, product portfolios, and strategic equity investment details. There is no presentation of financial statements, quarterly or annual results, nor is it a transcript of a call or a regulatory filing like an audit or certification. The content focuses on a capital financing event (strategic equity investment) and commercial partnership terms, which fits the category of Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive details about the financing and partnership, not just a brief announcement or a report publication notice. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-11-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.